{"id":832839,"date":"2025-04-02T08:08:47","date_gmt":"2025-04-02T12:08:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/labcorp-launches-first-of-its-kind-immunoassay-to-accelerate-path-to-diagnosis-of-alzheimers-disease\/"},"modified":"2025-04-02T08:08:47","modified_gmt":"2025-04-02T12:08:47","slug":"labcorp-launches-first-of-its-kind-immunoassay-to-accelerate-path-to-diagnosis-of-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/labcorp-launches-first-of-its-kind-immunoassay-to-accelerate-path-to-diagnosis-of-alzheimers-disease\/","title":{"rendered":"Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer’s Disease"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Labcorp’s pTau-217\/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer’s disease<\/i>\n <\/p>\n

\n
\n BURLINGTON, N.C.<\/span>
\n <\/span>, April 2, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217\/Beta Amyloid 42 Ratio<\/a>, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer’s disease. The new test further expands Labcorp’s leading blood-based biomarker portfolio for Alzheimer’s disease and dementia.<\/p>\n

\n

\n
\n \"Photo
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The pTau-217\/Beta Amyloid 42 Ratio supports neurologists, dementia specialists and their patients by offering results that are comparable to positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing obtained through lumbar puncture. Labcorp’s test meets performance criteria<\/a>\u00a0to confirm the presence of amyloid pathology consistent with Alzheimer’s disease, and, in connection with clinical findings, supports an accelerated path to diagnosis in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline.<\/p>\n

An estimated 6.9 million<\/a> Americans are living with Alzheimer’s disease, a number expected to nearly double by 2050. The average time between onset of symptoms and diagnosis of Alzheimer’s disease is approximately 2.8\u00a0years<\/a>. Today, an Alzheimer’s diagnosis often involves amyloid PET imaging and invasive CSF testing, which can be costly, time-consuming and uncomfortable.<\/p>\n

“For too many patients and their families, the journey from symptoms to diagnosis of Alzheimer’s disease can be long, difficult and uncertain,” said Dr.\u00a0Brian Caveney,\u00a0Labcorp’s\u00a0chief medical and scientific officer. “Our pTau-217\/Beta Amyloid 42 Ratio is a significant breakthrough, improving the diagnostic process for a complex disease. This test has the potential to reduce the time and anxiety associated with identifying Alzheimer’s disease, enabling patients and their families to make more timely and informed treatment decisions.”<\/p>\n

\n Key Features of Labcorp’s pTau-217\/Beta Amyloid 42 Ratioi<\/sup><\/b><\/b>\n <\/p>\n